New Clinical Trial to Test Effectiveness of Vorinostat (Zolinza) on Malignant Pleural Mesothelioma

The National Institute of Health Clinical Center has started to test the efficacy of vorinostat and the treatment of patients who have been diagnosed with pleural malignant mesothelioma. The trial is testing for toxicity levels and any side effects that may come about.

Dr, Raffit Hassan is the protocal chair of the, “A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (L-001079038) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy,” and can be contacted via the National Cancer Institutes's website.